Back to search results

Interventions for Promoting Kidney Transplant Empowerment

This study is looking at ways to help people get on the kidney transplant waitlist. It compares two approaches: "Usual Care," where doctors and nurses teach you about the transplant process, and an approach that adds "Community Health Worker Assistance." Community health workers help with social needs and connect you to services. Doctors and nurses involved in your care will also receive special training to reduce bias and improve how they communicate in your medical records. The study wants to see if these interventions help people complete their kidney transplant waitlisting evaluation faster. You might be able to join if you are 18-75 years old, have an eGFR (a measure of kidney function) of 20 or less, or are on dialysis. The study plans to enroll 5 people, but its current status is unclear.

Study design
This is a cluster randomized controlled clinical trial. It compares different care approaches, with providers and their patients assigned to a group. The study plans to enroll 5 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be checked at the beginning of the study, and then every 6 months for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06655857

Interventions for Promoting Kidney Transplant Empowerment

Recruiting
NAAges 18–75InterventionalHealth services
Icahn School of Medicine at Mount Sinai
~5 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:Usual CareCommunity Health Worker AssistanceIntervention Providers

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to completion of kidney transplant waitlisting evaluation
Measured over Baseline, and then every 6 months up to 2 years

Conditions

Kidney Transplant Waitlisting

Explore related trials

Chronic Kidney Disease

NCT06655857

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Montefiore Einstein

    The Bronx, New Yorkstudy coordinator listed

    Not yet recruiting

  • Mount Sinai Hospital

    New York, New Yorkstudy coordinator listed

    Recruiting

  • NYU Langone Health

    New York, New Yorkstudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Lili Chan · PRINCIPAL_INVESTIGATOR · Ichan School of Medicine at Mount Sinai Hospital

Who to contact

Lili Chan
[email protected]
929-618-0350
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient inclusion:
Provision of signed and dated informed consent from the patient.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Age 18 - 75 years
eGFR≤20 mL/min/1.73m2 or on maintenance in-center HD.
Receive kidney care at Mount Sinai, Einstein, Bellevue Hospital, NYU, or hemodialysis at a participating HD Center.
Community dwelling (i.e., not in a nursing home, currently incarcerated).
Speak English and/or Spanish.
Provider Inclusion:
Provision of signed and dated informed consent from the nephrologist.
Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion

Patient Exclusion:
Absolute contraindications to KTx:
Self-reported or documented diagnosis of dementia, or inability to understand the study and complete informed consent. When the participant's understanding is unclear, the CRC will use a modified MOCA screener to determine eligibility.
Active malignancy (excluding local non-melanoma skin cancer, renal cell carcinoma \<5 cm, early thyroid cancer, and prostate cancer GS≤6).
Pregnancy (can be re-evaluated post-delivery).
Active infection. Patients excluded due to active infection will be evaluated at 30 days or after completing full treatment (whichever is later) to determine eligibility. Examples of active infection include:
Positive cultures or radiographic evidence of infection
Infected intravascular devices, such as tunneled catheters and pacemakers
Active histoplasmosis, cryptococcosis, tuberculosis (TB), and nontuberculous mycobacteria
Previously evaluated by KTx and not listed for specific medical reasons.
Patients previously evaluated and not listed will be carefully reviewed by site PI for eligibility
Already listed for KTx.
Patients on other types of dialysis other than in-center hemodialysis.
Self-identify as already engaged with a CHW at participating sites to address unmet social needs.
Planning to move out of the greater NY area in the next 1 year.
Provider Exclusion:
Planning to leave their respective institutions in the next 1 year

What this trial measures

  • Time to completion of kidney transplant waitlisting evaluationBaseline, and then every 6 months up to 2 years

    Patient medical records will be reviewed, and the patient will be asked directly for the status of their kidney transplant evaluation.